Frejd FY - Search Results

1

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.

Malm M, Frejd FY, Ståhl S, Löfblom J. Malm M, et al. Among authors: frejd fy. MAbs. 2016 Oct;8(7):1195-1209. doi: 10.1080/19420862.2016.1212147. Epub 2016 Aug 17. MAbs. 2016. PMID: 27532938 Free PMC article. Review.

2

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.

Tolmachev V, Friedman M, Sandström M, Eriksson TL, Rosik D, Hodik M, Ståhl S, Frejd FY, Orlova A. Tolmachev V, et al. Among authors: frejd fy. J Nucl Med. 2009 Feb;50(2):274-83. doi: 10.2967/jnumed.108.055525. Epub 2009 Jan 21. J Nucl Med. 2009. PMID: 19164241 Free article.

3

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.

Friedman M, Lindström S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H, Gedda L, Frejd FY, Ståhl S. Friedman M, et al. Among authors: frejd fy. Biotechnol Appl Biochem. 2009 Aug 21;54(2):121-31. doi: 10.1042/BA20090096. Biotechnol Appl Biochem. 2009. PMID: 19492986

4

Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro.

Jonsson A, Wållberg H, Herne N, Ståhl S, Frejd FY. Jonsson A, et al. Among authors: frejd fy. Biotechnol Appl Biochem. 2009 Aug 17;54(2):93-103. doi: 10.1042/BA20090085. Biotechnol Appl Biochem. 2009. PMID: 19545237

5

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.

Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Löfblom J, et al. Among authors: frejd fy. FEBS Lett. 2010 Jun 18;584(12):2670-80. doi: 10.1016/j.febslet.2010.04.014. Epub 2010 Apr 11. FEBS Lett. 2010. PMID: 20388508 Free article. Review.

6

Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.

Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, Gedda L, Frejd FY, Ståhl S, Löfblom J. Kronqvist N, et al. Among authors: frejd fy. Protein Eng Des Sel. 2011 Apr;24(4):385-96. doi: 10.1093/protein/gzq118. Epub 2010 Dec 21. Protein Eng Des Sel. 2011. PMID: 21177282

7

Non-immunoglobulin based protein scaffolds.

Löfblom J, Frejd FY, Ståhl S. Löfblom J, et al. Among authors: frejd fy. Curr Opin Biotechnol. 2011 Dec;22(6):843-8. doi: 10.1016/j.copbio.2011.06.002. Epub 2011 Jul 2. Curr Opin Biotechnol. 2011. PMID: 21726995 Review.

8

Cellular effects of HER3-specific affibody molecules.

Göstring L, Malm M, Höidén-Guthenberg I, Frejd FY, Ståhl S, Löfblom J, Gedda L. Göstring L, et al. Among authors: frejd fy. PLoS One. 2012;7(6):e40023. doi: 10.1371/journal.pone.0040023. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768204 Free PMC article.

9

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

Ekerljung L, Wållberg H, Sohrabian A, Andersson K, Friedman M, Frejd FY, Ståhl S, Gedda L. Ekerljung L, et al. Among authors: frejd fy. Bioconjug Chem. 2012 Sep 19;23(9):1802-11. doi: 10.1021/bc3000645. Epub 2012 Aug 29. Bioconjug Chem. 2012. PMID: 22882002

10

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, Ståhl S, Löfblom J. Malm M, et al. Among authors: frejd fy. PLoS One. 2013 May 10;8(5):e62791. doi: 10.1371/journal.pone.0062791. Print 2013. PLoS One. 2013. PMID: 23675426 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page